Zobrazeno 21 - 30
of 153
pro vyhledávání: ''
Publikováno v:
Leukemialymphoma. 57(7)
One of the severe toxicities of pegaspargase (PEG) is the development of allergic reactions. This study retrospectively assessed 311 PEG doses administered to 139 acute lymphoblastic leukemia patients from May 1, 2008 to July 30, 2014 for allergic re
Autor:
Angela, Grelaud, Annie, Fourrier-Réglat, Olivier, Fitoussi, Thierry, Facon, Jérémy, Jové, Jacques, Bénichou, Philip, Robinson, Gérald, Marit, Magali, Rouyer, Nicholas, Moore, Pernelle, Noize, Miriam, Sturkenboom
Publikováno v:
Leukemialymphoma. 57(6)
Therapeutical options for older multiple myeloma patients have been improved with the advent of new drugs, yet there is a lack of observational data for such patients. To address this issue, an age-stratified analysis of the VESUVE cohort of bortezom
Autor:
Daniel Betticher, Katja Seipel, Sandra Keller, Beatrice U. Mueller, Behrouz Mansouri Taleghani, Thomas Pabst, Daniel Rauch, Thomas Egger
Publikováno v:
Mueller, Beatrice U; Keller, Sandra; Seipel, Katja; Mansouri Taleghani, Behrouz; Rauch, Daniel; Betticher, Daniel; Egger, Thomas; Pabst, Thomas (2015). Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity. Leukemia & lymphoma, 57(5), pp. 1122-1129. Informa Healthcare 10.3109/10428194.2015.1079315
Vinorelbine chemotherapy with granulocyte-colony stimulating factor (G-CSF) stimulation is a widely applied non-myelosuppressive mobilization regimen in Switzerland for myeloma patients, but its neurotoxic potential limits its use in patients with bo
Autor:
Chiara Pagani, Erika Borlenghi, Annamaria Pelizzari, Daniela Bellotti, Luisa Imberti, Cinzia Lamorgese, Francesca Schieppati, Leonardo Boiocchi, Giuseppe Rossi, Alessandra Sottini, Elisa Cerqui
Publikováno v:
Leukemialymphoma. 56(11)
"Real life" data are needed to complement published trials on the efficacy of lenalidomide in patients with myelodysplastic syndrome (MDS) and del(5q) and on the risk of inducing acute myeloid leukemia (AML) progression. Here, we present results of l
Autor:
Stanley J. Goldsmith, Morton Coleman, Scott Ely, June Greenberg, John P. Leonard, Peter Martin, Richard R. Furman, Jia Ruan, Sarah C. Rutherford
Publikováno v:
Leukemialymphoma. 56(11)
Milatuzumab (hLL1), a humanized anti-CD74 monoclonal antibody, has activity in preclinical non-Hodgkin lymphoma (NHL) models. We conducted a phase 1 trial in previously treated B-cell malignancies. Dose escalation included four planned dose levels (1
Autor:
Jennifer A. Woyach, Jeffrey A. Jones, Mitch A. Phelps, Farrukh T. Awan, Yonghua Ling, Weihong Chase, Yao Jiang, John C. Byrd, Kami J. Maddocks, Joseph M. Flynn, Leslie A. Andritsos, Margaret S. Lucas, David M. Lucas, Ellen J. Sass, Sharon Waymer
Publikováno v:
Leukemialymphoma. 56(10)
The proteasome complex degrades proteins involved in a variety of cellular processes and is a powerful therapeutic target in several malignancies. Carfilzomib is a potent proteasome inhibitor which induces rapid chronic lymphocytic leukemia (CLL) cel
Autor:
Perla R. Colunga-Pedraza, Mónica Andrea Pinzón-Uresti, José Luis Herrera-Garza, Olga G. Cantú-Rodríguez, David Gómez-Almaguer, José Carlos Jaime-Pérez, César Homero Gutiérrez-Aguirre
Publikováno v:
Leukemialymphoma. 56(9)
Remission induction regimens for acute lymphoblastic leukemia (ALL) in adults induce complete remission (CR) in 60-90% and cure in 20-40%. A cohort study of newly diagnosed patients with ALL treated with mitoxantrone versus doxorubicin was conducted
Autor:
Michela Staderini, Giovanni Longo, Chiara Nozzoli, Alberto Bosi, Alessio Veltroni, Francesca Bacchiarri, Agata Guarrera, Irene Donnini
Publikováno v:
Leukemialymphoma. 56(8)
The introduction of immunomodulatory drugs such as lenalidomide combined with dexamethasone (Len/Dex) has improved the outcome of patients with relapsed/refractory multiple myeloma (RRMM). Few data are currently available which investigate whether pa
Autor:
Robert Pytlik, Natasa Kopalova, Vít Procházka, Andrea Janíková, Vit Campr, Zbynek Bortlicek, Juraj Duras, Katerina Benesova, David Belada, Marek Trneny, Jiri Mayer, Jan Pirnos, Heidi Mocikova, Samuel Vokurka
Publikováno v:
Leukemialymphoma. 56(8)
Early-stage follicular lymphoma (FL) has traditionally been treated with involved-field radiotherapy (RT). Rituximab (R) is a low-toxic, efficient systemic therapy for FL, but there are no data about its clinical impact in early FL. We retrospectivel
Autor:
Ryan J. Mattison, Mark B. Juckett, Charles Erlichman, Betsy LaPlant, Alcee Jumonville, Patrick J. Flynn, Alvaro Moreno-Aspitia
Publikováno v:
Leukemialymphoma. 56(7)
Patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) not fit for intensive treatment need novel therapy options. Vascular endothelial growth factor (VEGF) receptor inhibition is one potential mechanism by which AML and MDS co